L3VLUP
ProSign in

IART · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IARTJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IART
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterIARTJNJ
Q3 20206 holders, $992m30 holders, $26.2bn
Q4 20206 holders, $1.4bn32 holders, $26.6bn
Q1 20214 holders, $1.5bn31 holders, $25.3bn
Q2 20216 holders, $1.5bn37 holders, $25.6bn
Q3 20216 holders, $1.7bn40 holders, $24.1bn
Q4 20216 holders, $1.6bn33 holders, $25.2bn
Q1 20228 holders, $1.3bn35 holders, $28.2bn
Q2 202210 holders, $969m33 holders, $26.9bn
Q3 202214 holders, $702m36 holders, $25.4bn
Q4 202211 holders, $946m35 holders, $27.6bn
Q1 202311 holders, $864m42 holders, $24.5bn
Q2 202312 holders, $492m38 holders, $25.0bn
Q3 202313 holders, $481m37 holders, $18.9bn
Q4 202310 holders, $530m31 holders, $19.0bn
Q1 20248 holders, $378m32 holders, $19.7bn
Q2 20246 holders, $212m35 holders, $20.4bn
Q3 20243 holders, $87m28 holders, $22.3bn
Q4 20243 holders, $60m37 holders, $20.4bn
Q1 20253 holders, $34m32 holders, $20.5bn
Q2 20252 holders, $2.8m31 holders, $18.4bn
Q3 20252 holders, $1.8m32 holders, $23.7bn
Q4 20251 holders, $662k29 holders, $27.8bn
Q1 20261 holders, $679k34 holders, $35.6bn
Q2 20261 holders, $1.8m33 holders, $39.1bn
IART

Integra Lifesciences Holdings Corp

Holders
3
Reported value
$60m
Buyers
2
Sellers
2

Breadth 0 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
37
Reported value
$20.4bn
Buyers
23
Sellers
12

Breadth +11 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 37 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IART (0)

None.

Only JNJ (34)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, and 9 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →